clinical efficacy of entecavir in treatment of hepatogenous diabetes
Clicks: 14
ID: 202219
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
3.9
/100
14 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #76 of 78 articles by views in lontar komputer
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ObjectiveTo observe the clinical efficacy of entecavir in the treatment of hepatogenous diabetes (HD). MethodsA retrospective analysis was performed on the clinical data of 72 HD patients, who were divided into treatment group (n=36) and control group (n=36). Both groups were given diabetic diet and received liver-protecting treatment, symptomatic treatment, and supportive treatment. In addition, the treatment group received oral entecavir (0.5 mg) once daily. The therapeutic effect was assessed after 52 weeks of treatment; the serum hepatitis B virus (HBV) DNA level, liver function (alanine aminotransferase, aspartate aminotransferase, total bilirubin, and albumin), blood glucose, and glycosylated hemoglobin were measured before and after treatment. The two groups were compared by t test (for measurement data) and chi-square test (for numeration data). ResultsAfter 52 weeks of treatment, 29 (80.56%) of the patients in treatment group had virological response, versus 7 (19.44%) of those in control group (χ2 = 18.00, P＜0.01); 26 (72.22%) of the patients in treatment group had liver function recovery and controlled diabetes, versus 16 (44.44%) of those in control group (χ2=5.774, P＜0.05). The treatment group showed significant improvements in liver function and blood glucose after treatment (P＜0.05); the treatment group had significantly lower glycosylated hemoglobin and fasting blood glucose than the control group (P＜0.01). ConclusionIn the treatment of HBV DNA-positive hepatitis B cirrhosis with HD, entecavir not only can effectively inhibit the replication of viral DNA and promote the recovery of liver function, but also can effectively control HD.
| Reference Key |
wei2013linchuangclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;GOU Wei |
| Journal | lontar komputer |
| Year | 2013 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.